Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy

[1]  R. Thompson,et al.  Emulating Target Clinical Trials of Radical Nephrectomy with or without Lymph Node Dissection for Renal Cell Carcinoma. , 2020, Urology.

[2]  U. Capitanio,et al.  Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. , 2020, Urologic oncology.

[3]  F. Saad,et al.  Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. , 2020, Urologic oncology.

[4]  R. Thompson,et al.  The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. , 2019, Urologic oncology.

[5]  W. Oyen,et al.  Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  P. Russo,et al.  The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. , 2019, Urologic oncology.

[7]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[8]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  U. Capitanio,et al.  Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma , 2018, World Journal of Urology.

[10]  P. Tamboli,et al.  Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging , 2018, Cancer.

[11]  William P. Parker,et al.  Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. , 2018, European urology.

[12]  U. Capitanio,et al.  The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta‐analysis , 2018, BJU international.

[13]  H. G. van der Poel,et al.  Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT Imaging , 2017, The Journal of urology.

[14]  N. Fleshner,et al.  Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. , 2017, Urologic oncology.

[15]  Jeffrey A. Cadeddu,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder lized Renal Cancer : AUA Guideline , 2017 .

[16]  J. Cheville,et al.  Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. , 2017, European urology.

[17]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  U. Capitanio,et al.  Extent of lymph node dissection at nephrectomy affects cancer‐specific survival and metastatic progression in specific sub‐categories of patients with renal cell carcinoma (RCC) , 2014, BJU international.

[19]  M. Menon,et al.  Node‐positive renal cell carcinoma in the absence of distant metastases: predictors of cancer‐specific mortality in a population‐based cohort , 2012, BJU international.

[20]  P. Tamboli,et al.  Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? , 2011, The Journal of urology.

[21]  M. Meng,et al.  Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. , 2011, The Journal of urology.

[22]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  S. Horenblas,et al.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Douglas G Altman,et al.  Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines , 2009, BMC medical research methodology.

[25]  I. White,et al.  Imputing missing covariate values for the Cox model , 2009, Statistics in medicine.

[26]  K. Bensalah,et al.  Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. , 2007, European urology.

[27]  C. Wood,et al.  Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. , 2006, The Journal of urology.

[28]  E. Bollito,et al.  Reassessing the current TNM lymph node staging for renal cell carcinoma. , 2006, European urology.

[29]  R. Figlin,et al.  Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. , 2003, The Journal of urology.

[30]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[31]  S. Hancock,et al.  Kidney cancer, version 3.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Y. Lotan,et al.  Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival. , 2014, Urologic oncology.

[33]  D. Jacqmin,et al.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.

[34]  B. Ljungberg.  Words of wisdom. Re: Radical nephrectomy with and without lymph-node dissection: final results of european organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.

[35]  B. Ljungberg.  Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881 , 2009 .

[36]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.